Astria Therapeutics Presents Findings on Burdens of Disease and Treatment in Hereditary Angioedema at the 2021 NORD Rare Diseases and Orphan Products Breakthrough Summit
18 October 2021 - 11:00PM
Business Wire
-- Substantial Need to Decrease Patient Burden
--
-- Findings Suggest Patients Are Interested in
Trying New Therapies that Offer Similar Efficacy and Less Frequent
Dosing --
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical
company developing STAR-0215 for the treatment of hereditary
angioedema (HAE), today presented “Burdens of Disease and Treatment
in Hereditary Angioedema: Interview Insights from HAE Patients,”
supporting that there is substantial need to address both HAE
disease burden and treatment burden with effective therapies that
have less frequent dosing. These findings were presented at the
2021 NORD Rare Diseases and Orphan Products Breakthrough
Summit.
“Our learnings from these findings support that there is a
substantial need for new HAE treatments, and that HAE patients are
open to trying new therapies that could reduce their disease and
treatment burdens,” said Andrew Komjathy, Chief Commercial Officer
at Astria Therapeutics. “Our goal with our preclinical program,
STAR-0215, is to provide the most patient-friendly preventative
treatment option for people living with HAE with dosing every three
months or longer. If we achieve our goals of demonstrating
reduction of treatment burden while maintaining efficacy, we are
hopeful that we can give patients the opportunity to focus their
time and energy on what matters most to them, rather than managing
their disease.”
The findings came from interviews of ten HAE patients using a
structured one-hour interview guide. Patients were screened for
inclusion based on self-identified disease type (HAE Types 1 and
2), disease severity (moderate or severe when not on treatment),
and eligibility for prophylactic treatment. Interviews covered
lifetime experiences with diagnosis, disease and treatment
management, advocacy, and perceptions of hypothetical improvements
in preventative therapy.
The findings suggest that HAE patients are seeking to reduce
their treatment burden as much as their disease burden and may be
open to trying new therapies that can address these needs. On
average, patients tried two to three preventative treatments, most
often switching for more convenient administration. Additionally,
despite being on preventative treatment, half of the patients
interviewed think about future attacks often or always. All
patients shared that they would be compelled to switch from their
current therapy if a new therapy offered similar efficacy with less
frequent dosing.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our
mission is to bring life-changing therapies to patients and
families affected by rare and niche allergic and immunological
diseases. Our lead program, STAR-0215, is a monoclonal antibody
inhibitor of plasma kallikrein in preclinical development for the
treatment of hereditary angioedema. Learn more about our company on
our website, www.astriatx.com, or follow us on Twitter and
Instagram @AstriaTx and on Facebook and LinkedIn.
Forward Looking Statements:
This press release contains forward-looking statements within
the meaning of applicable securities laws and regulations
including, but not limited to, statements regarding: the potential
attributes and differentiated profile of STAR-0215 as a treatment
for HAE; and the need for additional treatments for HAE. The use of
words such as, but not limited to, “anticipate,” “believe,”
“continue,” “could,” “estimate,” “expect,” “goals,” “intend,”
“may,” “might,” “plan,” “potential,” “predict,” “project,”
“should,” “target,” “will,” or “would” and similar words
expressions are intended to identify forward-looking statements.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based on the
Company’s current beliefs, expectations and assumptions regarding
the future of its business, future plans and strategies, future
financial performance, results of pre-clinical and clinical results
of the Company’s product candidates and other future conditions.
Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important
factors, including risks and uncertainties: related to changes in
applicable laws or regulations; the possibility that the Company
may be adversely affected by other economic, business, and/or
competitive factors, including the COVID-19 pandemic; risks
inherent in pharmaceutical research and development, such as:
adverse results in our drug discovery, preclinical and clinical
development activities, the risk that the results of pre-clinical
studies may not be replicated in clinical studies, the Company’s
ability to enroll patients in our clinical trials, and the risk
that any of the Company’s clinical trials may not commence,
continue or be completed on time, or at all; decisions made by, or
feedback received from, the U.S. FDA and other regulatory
authorities, investigational review boards at clinical trial sites
and other review bodies with respect to STAR-0215; the Company’s
ability to manufacture sufficient quantities of drug substance and
drug product for STAR-0215 on a cost-effective and timely basis;
the Company’s ability to obtain, maintain and enforce intellectual
property rights for STAR-0215; competition; as well as the risks
and uncertainties set forth under the caption “Risk Factors” in the
Company’s most recent Annual Report on Form 10-K filed with the
SEC, as well as discussions of potential risks, uncertainties, and
other important factors in the Company’s subsequent filings with
the SEC. New risks and uncertainties may emerge from time to time,
and it is not possible to predict all risks and uncertainties. The
Company may not actually achieve the forecasts or expectations
disclosed in our forward-looking statements, and investors and
potential investors should not place undue reliance on the
Company’s forward-looking statements. Neither the Company, nor its
affiliates, advisors or representatives, undertake any obligation
to publicly update or revise any forward-looking statement, whether
as result of new information, future events or otherwise, except as
required by law. These forward-looking statements should not be
relied upon as representing the Company’s views as of any date
subsequent to the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211018005041/en/
Astria Contacts:
Investor relations: Andrea Matthews
investors@astriatx.com
Media: Elizabeth Higgins media@astriatx.com
Astria Therapeutics (NASDAQ:ATXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astria Therapeutics (NASDAQ:ATXS)
Historical Stock Chart
From Apr 2023 to Apr 2024